Narcolepsy: vizsgálatok itt: Olaszország
14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 2/3. fázisNot yet taking people in OlaszországA Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence
- Where
- Bologna, Rome, Verona
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Centessa Pharmaceuticals UK Limited
See details and how to join2026-525961-37-00 - 2/3. fázisTaking peopleA Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
- Where
- Bologna, Genoa, Milan, Pavia, Rome, Verona
- Életkor
- 18 év to 70 év
- People
- 786 worldwide
- Run by
- Alkermes, Inc.
See details and how to joinNCT06767683 · EU 2024-519822-18-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
- Where
- Bologna, Milan, Rome, Verona
- Életkor
- 18 év and over
- People
- 116 worldwide
- Run by
- Alkermes Inc.
See details and how to join2025-524711-36-00 - 2. fázisTaking peopleA Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
- Where
- Bologna, Rome, Verona
- Életkor
- 18 év to 70 év
- People
- 88 worldwide
- Run by
- Takeda
See details and how to joinNCT06952699 · EU 2024-517711-70-01 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
- Where
- Verona
- Életkor
- 18 év to 70 év
- People
- 150 worldwide
- Run by
- Alkermes, Inc.
See details and how to joinNCT07455383 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
- Where
- Bologna
- Életkor
- 18 év to 70 év
- People
- 176 worldwide
- Run by
- Alkermes, Inc.
See details and how to joinNCT07502443 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
- Where
- Bologna, Genoa, Milan, Pavia, Rome, Verona
- Életkor
- 18 év and over
- People
- 115 worldwide
- Run by
- Alkermes Inc.
See details and how to join2025-523911-13-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
- Where
- Bologna, Genoa, Milan, Pavia, Rome, Verona
- Életkor
- 18 év and over
- People
- 132 worldwide
- Run by
- Alkermes Inc.
See details and how to join2025-523912-35-00 - 3. fázisTaking peopleA Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
- Where
- Bologna, Milan, Pisa, Rome
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- Harmony Biosciences Management, Inc.
See details and how to joinNCT07675135 · EU 2025-523821-17-00 - 2. fázisTaking peopleA Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
- Where
- Bologna, Verona
- Életkor
- 18 év to 70 év
- People
- 92 worldwide
- Run by
- Takeda
See details and how to joinNCT07633301 · EU 2025-522587-33-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
- Where
- Bologna, Pavia, Verona
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT07493265 - 2. fázisTaking peopleA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Where
- Bologna, Pozzilli, Verona
- Életkor
- 18 év to 65 év
- People
- 248 worldwide
- Run by
- Centessa Pharmaceuticals (UK) Limited
See details and how to joinNCT06752668 · EU 2024-518929-15-00 - 2. fázisTaking peopleA Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Where
- Bologna, Pozzilli, Verona
- Életkor
- 18 év to 65 év
- People
- 90 worldwide
- Run by
- Centessa Pharmaceuticals (UK) Limited
See details and how to joinNCT07096674 · EU 2025-522987-34-00 - 2/3. fázisTaking peopleA Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
- Where
- Bologna, Pozzilli, Rome, Verona
- Életkor
- 16 év to 70 év
- People
- 500 worldwide
- Run by
- Takeda
See details and how to joinNCT05816382 · EU 2023-508462-15-00